Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis.

Trial Profile

Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Plitidepsin (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Additional trial identifier APL-B020-10 identified and lead trial investigator as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top